| Q53526491 | 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma. |
| Q43579501 | Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials |
| Q46799392 | Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences |
| Q38649847 | Brentuximab vedotin in CD30(+) primary cutaneous T-cell lymphomas: a review and analysis of existing data. |
| Q64109981 | CD4/CD8 Double-negative Mycosis Fungoides: A Case Report and Literature Review |
| Q52018886 | CD45RA+ immunophenotype in mycosis fungoides: clinical, histological and immunophenotypical features in 22 patients. |
| Q94340486 | Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma |
| Q46008292 | Cutaneous T-cell lymphoma associated with ileostomy: management of uncommon stomal complication. |
| Q37398969 | Cutaneous T-cell lymphoma in sub-Saharan Africa |
| Q24650893 | Denileukin diftitox for the treatment of cutaneous T-cell lymphoma |
| Q40173571 | Early changes in miRNA expression are predictive of response to extracorporeal photopheresis in cutaneous T-cell lymphoma |
| Q50002389 | Early-stage mycosis fungoides screening investigations: a retrospective analysis of 440 cases |
| Q37809875 | Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies |
| Q39503272 | Evaluation of neutrophil-lymphocyte ratio in patients with early-stage mycosis fungoides |
| Q31036179 | Expression of cancer/testis antigens in cutaneous T cell lymphomas |
| Q40468663 | Fine mapping of chromosome 10q deletions in mycosis fungoides and sezary syndrome: identification of two discrete regions of deletion at 10q23.33-24.1 and 10q24.33-25.1. |
| Q98283428 | Gene expression profile identifies distinct molecular subtypes and potential therapeutic genes in Merkel cell carcinoma |
| Q52932626 | Histologic criteria for the diagnosis of mycosis fungoides: proposal for a grading system to standardize pathology reporting. |
| Q35584244 | Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation |
| Q24200749 | Interventions for mycosis fungoides |
| Q24235242 | Interventions for mycosis fungoides |
| Q36059635 | Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome |
| Q37379370 | Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. |
| Q35567170 | Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients |
| Q35545023 | Lymphomatoid papulosis associated with mycosis fungoides: a study of 21 patients including analyses for clonality |
| Q35583232 | Management of the primary cutaneous lymphomas |
| Q36962214 | Mycosis fungoides and Sezary syndrome against a human immunodeficiency virus-positive background: case report |
| Q34761883 | Mycosis fungoides and Sézary syndrome |
| Q37296614 | Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors |
| Q36262715 | Mycosis fungoides: A case report |
| Q38011745 | Myxoid variant of anaplastic large cell lymphoma involving the skin: a case report |
| Q56828372 | Neoplasms |
| Q79256082 | Outcome in 34 patients with juvenile-onset mycosis fungoides: a clinical, immunophenotypic, and molecular study |
| Q35808399 | Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches |
| Q33386623 | Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma |
| Q33339001 | Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma |
| Q30747958 | Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma |
| Q38196931 | Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? |
| Q53039521 | Prognostic indicators for mycosis fungoides in a Greek population. |
| Q57561035 | Quantitation of tumour development correlates with prognosis in tumour stage (stage IIB) mycosis fungoides |
| Q38230665 | Racial differences in the use of extracorporeal photopheresis for mycosis fungoides |
| Q37444717 | Review of the treatment of mycosis fungoides and Sézary syndrome: A stage-based approach |
| Q35186682 | Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma |
| Q35683831 | Romidepsin in the treatment of cutaneous T-cell lymphoma |
| Q41342946 | Second Primary Malignancies in CTCL Patients from 1992 to 2011: A SEER-Based, Population-Based Study Evaluating Time from CTCL Diagnosis, Age, Sex, Stage, and CD30+ Subtype |
| Q33796958 | Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial |
| Q33746059 | The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indications |
| Q36771218 | The diagnosis, staging, and treatment options for mycosis fungoides |
| Q34037897 | The influence of the coexpression of CD4 and CD8 in cutaneous lesions on prognosis of mycosis fungoides: a preliminary study. |
| Q47654977 | Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas |
| Q44630716 | Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial |
| Q44691746 | Topical imiquimod therapy for cutaneous T-cell lymphoma |
| Q43975407 | Treatment of cutaneous T-cell lymphoma with alitretinoin gel. |
| Q36609811 | Treatment of cutaneous T-cell lymphoma with retinoids |
| Q46942684 | Treatment of cutaneous T-cell lymphomas with bexarotene |
| Q43064391 | Vaginal obliteration in a woman with a history of cutaneous T-cell lymphoma: the results of combined chemotherapy-induced gonadal toxicity and lymphoma relapse |
| Q80349901 | [Frequency of associated malignancies in cutaneous lymphomas: a retrospective study of 86 cases] |